Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list

Transpl Int. 2014 Jul;27(7):686-95. doi: 10.1111/tri.12323. Epub 2014 Apr 25.

Abstract

The model of end-stage liver disease (MELD) score is often used for liver graft allocation, and patients with hepatocellular carcinoma (HCC) receive exception points (22 in the US). A better model is desirable for patients with HCC as they tend to have a privileged access to transplantation, without taking HCC characteristics into account. A new simpler model designed from a training set of US patients (n = 49 026) was tested on two validation sets (US and UK patient cohorts with, respectively, n = 20 475 and n = 1781). The risk of dropout was between 3.2 and 7.8% at 3 months in patients with HCC, and was captured into a score, including HCC size, HCC number, AFP, and MELD (-37.8 +1.9*MELD+5.9 if HCC Nb ≥ 2 + 5.9 if AFP > 400 + 21.2 if HCC size > 1 cm). This new model could be validated on external US and UK liver candidate cohorts. It provides a dynamic and more accurate assessment of dropout than the use of exception MELD (C-indices of 66.2-73.7% vs. 52.7-56.6%). In addition, the model shows a similar distribution as MELD for patients with non-HCC, and both scores could be used in parallel for the management of waiting-list patients with and without HCC.

Keywords: MELD; allocation; deMELD; score; validation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Carcinoma, Hepatocellular / pathology*
  • Carcinoma, Hepatocellular / surgery
  • End Stage Liver Disease / pathology
  • End Stage Liver Disease / surgery*
  • Female
  • Health Care Rationing
  • Humans
  • Liver Neoplasms / pathology*
  • Liver Neoplasms / surgery
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Patient Dropouts*
  • Patient Selection
  • Predictive Value of Tests
  • Severity of Illness Index
  • United Kingdom
  • United States
  • Waiting Lists*